Skip to main content

Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease

Completed · NCT05365490

Conditions: Carotid Artery Diseases

At a glance

Research payments reported, 2025
$190,538
U.S. investigators named
41
Sites paid
44
Planned or actual enrollment
344

About the trial

Sponsor
Silk Road Medical
Tested
Transcarotid Artery Revascularization (TCAR) (procedure)
Dates
Started 2022-09-01; completion 2025-07-22
Results posted
Not yet

The study objective is to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System in patients at standard risk for adverse events from carotid endarterectomy

From ClinicalTrials.gov, last updated 2025-07-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $190,538 in research payments for this study in 2025 (118 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.